GLP‑1 drugs and muscle loss
A systematic review of 36 randomized trials flagged that GLP‑1 receptor agonists — the weight‑loss drugs many people use — can reduce muscle mass as well as fat, which makes resistance training and protein intake more important for users. (cedclinic.com) The U.S. Anti‑Doping Agency has also published guidance for competitive athletes on using GLP‑1s, and researchers are pointing to genetic differences as one reason some people respond very differently to these drugs. (cedclinic.com) (calgarysun.com)
GLP-1 drugs help people lose weight by cutting appetite and slowing how fast food leaves the stomach, but some of that weight can come from muscle as well as fat. (pubmed.ncbi.nlm.nih.gov) A 2025 systematic review and meta-analysis in *Obesity Reviews* pooled 38 publications with 1,735 participants and found a significant drop in muscle-mass measures in people without diabetes taking glucagon-like peptide-1 receptor agonists: about 1.41 kilograms on average, versus 6.02 kilograms of fat mass. In that analysis, muscle accounted for less than 20% of total weight lost. (pubmed.ncbi.nlm.nih.gov) A separate 2025 meta-analysis of 36 randomized controlled trials covering 2,555 participants found that these drugs consistently reduced fat mass and that lean-mass loss showed up in most studies, especially in people with overweight or obesity and in longer treatment. The authors reported the lean-mass signal was clearest when GLP-1 drugs were compared with placebo. (pubmed.ncbi.nlm.nih.gov) Doctors track that split because muscle is the tissue that helps people stay strong, keep balance, and maintain metabolism during weight loss. A 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society lists muscle and bone loss among the main challenges clinicians should watch during GLP-1 treatment. (pmc.ncbi.nlm.nih.gov) That advisory says care should not stop at the prescription pad. It recommends baseline checks of muscle strength, function, and body composition, along with strength training, diet review, and other lifestyle support during treatment. (pmc.ncbi.nlm.nih.gov) Exercise already has trial data behind it. In a 2021 *New England Journal of Medicine* trial, adults with obesity who used liraglutide plus a moderate-to-vigorous exercise program after an 8-week low-calorie diet maintained weight loss better than people assigned to either strategy alone. (nejm.org) The athlete question has moved from locker-room rumor to formal guidance. The U.S. Anti-Doping Agency said this week that GLP-1 drugs are not prohibited in sport, do not require a Therapeutic Use Exemption, and are being monitored by the World Anti-Doping Agency for possible future review. (usada.org) USADA also warned athletes about unapproved products sold online and on social media. Its guidance lists semaglutide brands including Ozempic and Wegovy, and says approved uses in the U.S. include type 2 diabetes, chronic weight management, and, for some products, cardiovascular-risk reduction or obstructive sleep apnea. (usada.org) (fda.gov) (accessdata.fda.gov) Researchers are also finding that patients do not respond the same way to these drugs. A 2025 study in *Obesity* genotyped 112 people with severe obesity on semaglutide 2.4 milligrams weekly and found that a variant in the GLP1R gene, plus sex, independently predicted how fast they lost weight over four months. (pubmed.ncbi.nlm.nih.gov) In that study, patients with two copies of the A variant lost weight at an average rate of 1.64% per month, compared with 1.04% per month in carriers of at least one G variant. Women with the AA genotype lost weight fastest, while 56% of men carrying the G allele were classified as nonresponders. (pubmed.ncbi.nlm.nih.gov) The practical message is narrower than the hype around these drugs: the scale can go down while strength slips with it. That is why newer guidance pairs GLP-1 treatment with resistance training, nutrition support, and closer follow-up on what kind of weight a patient is actually losing. (pmc.ncbi.nlm.nih.gov)
